Abstract
To date, implementation of precision medicine for children has been limited. Extrapolation of adult experience streamlines pediatric drug development programs, and physiologically based pharmacokinetic models aid pediatric dose selection on a population basis. To achieve clinically viable individualization of drug therapy, genotype-stratified pharmacokinetic studies can efficiently characterize the extremes of the dose-exposure relationship. Reducing variability in exposure through genotype-based dosing may improve identification of genetic factors contributing to response, ultimately improving drug therapy for children.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
